$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
How to effectively manage adverse reactions and side effects during treatment with mivamutide?
2026-02-01 22:25:32
Check Details
Can mivamutide be used in combination with other cancer treatments?
2026-02-01 22:25:32
Check Details
Zolbetuximab-Vyloy Latest Market Price 2025: How It Affects Patient Treatment Choices
2026-02-01 22:25:32
Check Details
Roprestim/Romigrastim and Qilu Pharmaceutical: Hope and Prospects of Domestic Generic Drugs
2026-02-01 22:25:32
Check Details
Is midostaurin effective in treating diseases?
2026-02-01 22:25:32
Check Details
Cabergoline packaging color reveal: What is the difference between pink and blue packaging?
2026-02-01 22:25:32
Check Details
Molotinib/mometinib wins Canadian approval for the treatment of myelofibrosis with anemia
2026-02-01 22:25:32
Check Details
Where can I buy Zolbetuximab-Vyloy? How to obtain medicines and precautions
2026-02-01 22:25:32
Check Details
The latest price analysis of the targeted drug trametinib in 2025: How do patients choose the most economical treatment option?
2026-02-01 22:25:32
Check Details
Analysis of side effects of dabrafenib/dabrafenib: How do patients cope with discomfort during treatment?
2026-02-01 22:25:32
Check Details
The latest price of Roprestimin/Romigrastim in 2025: How patients can choose the most economical treatment option
2026-02-01 22:25:32
Check Details
Detailed instructions for Zolbetuximab-Vyloy: indications, usage, dosage and precautions
2026-02-01 22:25:32
Check Details
1
2
...
1330
1331
1332
1333
1334
1335
1336
...
10239
10240
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Ribociclib: Mechanism of Action and Approved Uses in Breast Cancer
2
Revumenib: Key Considerations Before and During Treatment
3
Pacritinib in Myelofibrosis: Evidence on Spleen Volume Reduction and Symptom Control
4
Binimetinib + Encorafenib: Dual MEK/BRAF Targeting in BRAF+ Tumors
5
Neratinib Dosing: 240mg Start, Diarrhea Prophylaxis, Hepatic Adjustment
6
Pomalidomide vs Thalidomide: IMiD Generation Gap and MM Use
7
Dasatinib: A BCR-ABL Targeted TKI, Not Conventional Chemo
8
Obeticholic Acid (OCA): FXR Therapy in PBC and Liver Safety Limits
9
Selumetinib and KRAS Mutations: Where the MEK Inhibitor Actually Fits
10
Erdafitinib in Lung Squamous Cell Carcinoma: Indication Boundaries and FGFR Interpretation
11
Eltrombopag: TPO-Receptor Agonist in ITP and Severe Aplastic Anemia
12
Ganaxolone for CDKL5-Related Seizures: GABA-A Modulation, Not a Cure